

NICE Guidance: Continuous Glucose Monitoring

Kelly Broad, Deputy Chief Pharmacist,
Cambridgeshire & Peterborough Integrated Care Board



31st March 2022

“NICE recommends the use of continuous glucose monitoring (CGM) for adults and children living with type 1 diabetes” and a cohort of adults living with type 2 diabetes.





Cambridgeshire & Peterborough Baseline (April 2022)




32% of children (Type 1)
< 19years not on CGM



61% of adults (Type 1)
not on CGM



100% of adults (Type 2
cohort) not on CGM



The Review Process



February 2022

- System engagement including Diabetes UK – what was possible and how?
- Limited choice of devices available

£££

April 2022 – June 2022


- Forecast against published guidance
- Horizon scanning – devices in the pipeline
- Transition from Clinical Commissioning Group to Integrated Care System

££

July 2022 – October 2022

- Greater device options (primary and secondary care)
- Impact on workforce
- Economic modelling against patient outcomes (physical)

£




Economic Modelling

How do we balance the in year investment against the longer-term benefits?

Investment of £2.2 million in Diabetes Monitoring Technology



559 fewer ambulance call outs per annum




47% decrease in non-elective activity related to low blood glucose levels (hypoglycaemia)



By year 3, improved patient outcomes will supersede technology costs



Implementation Factors and Challenges




Cambridgeshire & Peterborough (August 2023)



97% of children
(Type 1)
< 19 years using
rtCGM



3887 adults are
using CGM
prescribable on FP10





With thanks to:

- Cambridge University Hospitals NHS Foundation Trust
- North West Anglia NHS Foundation Trust
- Cambridgeshire and Peterborough NHS Foundation Trust
- Cambridgeshire and Peterborough Diabetes UK Local Support Group
- Cambridgeshire and Peterborough Primary Care Networks
- Cambridgeshire and Peterborough Community Pharmacies